Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2020 Earnings Conference Call - Final Transcript
May 11, 2020 • 04:30 pm ET
Greetings, and welcome to Pulse Biosciences First Quarter 2020 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host Philip Taylor, Investor Relations of Pulse Biosciences. Thank you. You may begin.
Thank you, operator. I hope that you all are keeping well during this time. We are hosting our call from a number of different locations today. So please bear with us, if there are any technical challenges or pauses. Before we begin, I would like to inform you that comments and responses to your questions during today's call reflects management's views as of today, May 11, 2020 only, and will include forward-looking statements and opinion statements.
These include statements regarding our plans and expectations relating to regulatory clearance, including the process, timelines and expected outcomes, our commercial, operational, scientific, clinical and financial projections, product including the uses and applications of such products, the impact of the COVID-19 pandemic on our business, our expectations regarding our rights offering including our ability to raise capital and other future events.
Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in our filings with the SEC including our most recent Form 10-K filed on March 16, 2020. We undertake no obligation to update forward looking statements. Our SEC filings can be found through our website or at the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements.
Please note, that this conference call will be available for audio replay on our website at pulsebiosciences.com on the News and Events section of our Investor Relations page.
With that, I would now like to turn the call over to President and Chief Executive Officer, Darrin Uecker.
Thank you all for joining us this afternoon Middle-East time times. I'm going to start with thanking all of the healthcare front liners, essential workers and first responders currently supporting all of us through the COVID-19 crisis. Our thoughts are with everyone who has been impacted by [Technical Issue] and while we have faced -- unprecedented circumstances in the last several months, as we adapt to the challenges brought about by COVID-19. We remain optimistic about the near-term and long-term prospects for Pulse Biosciences and our Nano-Pulse Stimulation technology.
As with all companies during this unusual time here at Pulse Biosciences, the number one priority is the safety of our employees. And we have been diligent and taking precautions to mitigate the risk of COVID-19 infection in our community. On March 16th, we closed our office and for the safety of our employees instituted a work from home policy, consistent with a shelter in place order that was announced in the San Francisco Bay Area counties of Northern California, which includes Alameda County where our headquarters are located. We